trending Market Intelligence /marketintelligence/en/news-insights/trending/qP6ehNnZl_Gh8Gy-QvWHhQ2 content esgSubNav
In This List

US FDA accepts VBI Vaccines application for brain tumor drug

Blog

Gauging Supply Chain Risk In Volatile Times

Blog

Insight Weekly: Banks' efficiency push; vacuuming carbon; Big Pharma diversity goals

Blog

The Future of Risk Management Digitization in Credit Risk Management

Blog

Climate Credit Analytics: Diving into the model


US FDA accepts VBI Vaccines application for brain tumor drug

The U.S. Food and Drug Administration accepted VBI Vaccines Inc.'s investigational new drug application for VBI-1901, an immunotherapy to treat glioblastoma multiforme.

Glioblastoma multiforme is the most common and aggressive malignant primary brain tumors in humans.

VBI Vaccines intends to evaluate the drug in the second half of 2017 in a phase 1/2a clinical trial in patients with recurrent glioblastoma multiforme.